MRK.BA : Summary for MERCK & CO INC CEDEAR (10 REP 1 - Yahoo Finance

U.S. Markets open in 3 hrs 31 mins

Merck & Co., Inc. (MRK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
98.850.00 (0.00%)
At close: 2:28 PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close98.85
Bid0.00 x
Ask105.00 x
Day's Range98.85 - 98.85
52 Week Range98.85 - 98.85
Avg. Volume937
Market Cap2.6T
PE Ratio (TTM)50.49
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Forbes22 hours ago

    Merck CEO Ken Frazier Is A Quote Machine

    Frazier took the stage at Forbes Healthcare Summit in New York to discuss the changing landscape of cancer treatment with fellow heavy hitters and shared his thoughts on everything from cost vs. value to how one drug breakthrough leads to others.

  • American City Business Journals3 days ago

    Tech Data’s board gets more diverse with addition of former Merck executive

    Tech Data Corp. has doubled the number of women on its board of directors. Bridgette Heller, a member of the executive committee of French food products company Danone, was appointed to the Tech Data (TECD) board late last month. Diverse companies are more likely to have financial returns above their national industry medians, and are better able to win top talent and improve their customer orientation, according to management consulting firm McKinsey & Co.

  • Market Realist3 days ago

    AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy

    AbbVie (ABBV) and Roche Holdings (RHHBY) have completed a Phase 1 trial evaluating the use of Venclexta as a therapy for multiple myeloma patients.